Akalin A, Elmore L W, Forsythe H L, Amaker B A, McCollum E D, Nelson P S, Ware J L, Holt S E
Department of Pathology, Massey Cancer Center, Medical College of Virginia at Virginia Commonwealth University, Richmond, Virginia 23298, USA.
Cancer Res. 2001 Jun 15;61(12):4791-6.
Telomerase activity has been detected in >85% of all malignant human cancers, including 90% of prostate carcinomas. Using a well-characterized experimental prostate cancer system, we have found that telomerase activity is notably increased (>10-fold) during tumorigenic conversion. Expression profiles of the telomerase components (hTR and hTERT) revealed no substantive changes, which suggests a nontranscriptional mechanism for increased activity. Because the hsp90 chaperone complex functionally associates with telomerase, we investigated that relationship and found that along with telomerase activity, a number of hsp90-related chaperones are markedly elevated during transformation, as well as in advanced prostate carcinomas. Using the nontumorigenic cell protein extract as the source of telomerase, addition of purified chaperone components enhanced reconstitution of telomerase activity, which suggests a novel mechanism of increased telomerase assembly via a hsp90 chaperoning process during prostate cancer progression.
在所有人类恶性肿瘤中,超过85%检测到端粒酶活性,其中90%的前列腺癌也有该活性。利用一个特征明确的实验性前列腺癌系统,我们发现,在致瘤转化过程中端粒酶活性显著增加(超过10倍)。端粒酶组分(hTR和hTERT)的表达谱没有实质性变化,这表明活性增加存在非转录机制。由于热休克蛋白90(hsp90)伴侣复合体在功能上与端粒酶相关联,我们研究了这种关系,发现与端粒酶活性一样,在转化过程以及晚期前列腺癌中,一些与hsp90相关的伴侣蛋白显著升高。以非致瘤性细胞蛋白提取物作为端粒酶来源,添加纯化的伴侣蛋白组分可增强端粒酶活性的重建,这表明在前列腺癌进展过程中,通过hsp90伴侣过程增加端粒酶组装存在一种新机制。